Rasha Abdelhady, Rana M. Abdelnaby, Mohamed Elsayed Mohamed Amer, Nancy S. Younis, Ebtehal Mohammad Fikry
{"title":"吡格列酮调节TLR4和上调HO-1和PPAR-γ可改善甲氨蝶呤诱导的大鼠肝损伤","authors":"Rasha Abdelhady, Rana M. Abdelnaby, Mohamed Elsayed Mohamed Amer, Nancy S. Younis, Ebtehal Mohammad Fikry","doi":"10.1186/s43094-025-00819-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Methotrexate is a frequently prescribed antifolate immunosuppressant and antineoplastic agent that has been associated with serious systemic adverse effects including hepatotoxicity. The current investigation explored the efficacy of the peroxisome proliferator activated receptor-gamma (PPAR-γ) agonist, Pioglitazone, in modulating Methotrexate-provoked liver damage then elucidating the underlying molecular mechanisms. Rats were allocated into four groups (<i>n</i> = 6): control group (received saline orally); Pioglitazone-exposed group (administered Pioglitazone 4 mg/kg/day p.o. from day 15 to 28); Methotrexate-treated group, (received Methotrexate 14 mg/kg/week p.o. from day 1 to 14); and Methotrexate and Pioglitazone-treated group (received Methotrexate form day 1 to 14 then received Pioglitazone from day 15 to 28 at the previously specified doses). </p><h3>Results</h3><p>The findings of the current work demonstrated that Pioglitazone alleviated Methotrexate-induced liver injury as depicted by correcting Methotrexate-induced elevation of liver enzymes, namely, alanine aminotransferase plus aspartate aminotransferase as well as ameliorating Methotrexate-induced histopathological changes. Accordingly, Pioglitazone administration in Methotrexate-intoxicated rats partially restored the redox homeostasis as manifested by suppressing malondialdehyde alongside elevating reduced glutathione contents. Notably, all previously mentioned parameters were measured using colorimetric assays. Remarkably, the reported hepatoprotective effect is putatively mediated through hindering hepatic inflammation reflected by the reported upregulation of PPAR-γ and hemoxygenase-1 with subsequent suppression of nuclear factor-kappa B and tumor necrosis factor-α. Additionally, current findings revealed modulation of Toll-like receptor 4 following Pioglitazone treatment that was further confirmed by our in silico study. </p><h3>Conclusions</h3><p>Therefore, this investigation suggests Pioglitazone as a promising therapeutic intervention in mitigating Methotrexate-induced liver injury.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00819-1","citationCount":"0","resultStr":"{\"title\":\"Modulation of TLR4 and upregulation of HO-1 & PPAR-γ by Pioglitazone ameliorates methotrexate-induced liver damage in rats\",\"authors\":\"Rasha Abdelhady, Rana M. Abdelnaby, Mohamed Elsayed Mohamed Amer, Nancy S. Younis, Ebtehal Mohammad Fikry\",\"doi\":\"10.1186/s43094-025-00819-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Methotrexate is a frequently prescribed antifolate immunosuppressant and antineoplastic agent that has been associated with serious systemic adverse effects including hepatotoxicity. The current investigation explored the efficacy of the peroxisome proliferator activated receptor-gamma (PPAR-γ) agonist, Pioglitazone, in modulating Methotrexate-provoked liver damage then elucidating the underlying molecular mechanisms. Rats were allocated into four groups (<i>n</i> = 6): control group (received saline orally); Pioglitazone-exposed group (administered Pioglitazone 4 mg/kg/day p.o. from day 15 to 28); Methotrexate-treated group, (received Methotrexate 14 mg/kg/week p.o. from day 1 to 14); and Methotrexate and Pioglitazone-treated group (received Methotrexate form day 1 to 14 then received Pioglitazone from day 15 to 28 at the previously specified doses). </p><h3>Results</h3><p>The findings of the current work demonstrated that Pioglitazone alleviated Methotrexate-induced liver injury as depicted by correcting Methotrexate-induced elevation of liver enzymes, namely, alanine aminotransferase plus aspartate aminotransferase as well as ameliorating Methotrexate-induced histopathological changes. Accordingly, Pioglitazone administration in Methotrexate-intoxicated rats partially restored the redox homeostasis as manifested by suppressing malondialdehyde alongside elevating reduced glutathione contents. Notably, all previously mentioned parameters were measured using colorimetric assays. Remarkably, the reported hepatoprotective effect is putatively mediated through hindering hepatic inflammation reflected by the reported upregulation of PPAR-γ and hemoxygenase-1 with subsequent suppression of nuclear factor-kappa B and tumor necrosis factor-α. Additionally, current findings revealed modulation of Toll-like receptor 4 following Pioglitazone treatment that was further confirmed by our in silico study. </p><h3>Conclusions</h3><p>Therefore, this investigation suggests Pioglitazone as a promising therapeutic intervention in mitigating Methotrexate-induced liver injury.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00819-1\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00819-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00819-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Modulation of TLR4 and upregulation of HO-1 & PPAR-γ by Pioglitazone ameliorates methotrexate-induced liver damage in rats
Background
Methotrexate is a frequently prescribed antifolate immunosuppressant and antineoplastic agent that has been associated with serious systemic adverse effects including hepatotoxicity. The current investigation explored the efficacy of the peroxisome proliferator activated receptor-gamma (PPAR-γ) agonist, Pioglitazone, in modulating Methotrexate-provoked liver damage then elucidating the underlying molecular mechanisms. Rats were allocated into four groups (n = 6): control group (received saline orally); Pioglitazone-exposed group (administered Pioglitazone 4 mg/kg/day p.o. from day 15 to 28); Methotrexate-treated group, (received Methotrexate 14 mg/kg/week p.o. from day 1 to 14); and Methotrexate and Pioglitazone-treated group (received Methotrexate form day 1 to 14 then received Pioglitazone from day 15 to 28 at the previously specified doses).
Results
The findings of the current work demonstrated that Pioglitazone alleviated Methotrexate-induced liver injury as depicted by correcting Methotrexate-induced elevation of liver enzymes, namely, alanine aminotransferase plus aspartate aminotransferase as well as ameliorating Methotrexate-induced histopathological changes. Accordingly, Pioglitazone administration in Methotrexate-intoxicated rats partially restored the redox homeostasis as manifested by suppressing malondialdehyde alongside elevating reduced glutathione contents. Notably, all previously mentioned parameters were measured using colorimetric assays. Remarkably, the reported hepatoprotective effect is putatively mediated through hindering hepatic inflammation reflected by the reported upregulation of PPAR-γ and hemoxygenase-1 with subsequent suppression of nuclear factor-kappa B and tumor necrosis factor-α. Additionally, current findings revealed modulation of Toll-like receptor 4 following Pioglitazone treatment that was further confirmed by our in silico study.
Conclusions
Therefore, this investigation suggests Pioglitazone as a promising therapeutic intervention in mitigating Methotrexate-induced liver injury.
期刊介绍：
Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
